On June 11, 2010, the FDA published its draft guidance entitled “Bioequivalence Recommendations for Specific Products.” This draft guidance “explained the process that would be used to make product-specific BE recommendations available to the public on FDA’s Web site.”
On January 28, 2016, FDA published product-specific recommendations regarding the design of bioequivalence (BE) studies used to support abbreviated new drug applications (ANDAs). The BE recommendations identified in FDA’s guidance were developed using the process described in the June 2010 guidance.
FDA’s guidance contains [new] draft recommendations for 31 different active pharmaceutical ingredients (APIs), including:
In addition, the Agency also released revised draft recommendations for the following 11 APIs:
FDA is seeking feedback from the public and will be accepting comments until March 28, 2016.
Do you have a generic product on its way to approval? Is your product already approved by an ANDA? We can help you obtain approval for your product and maintain compliance with all applicable FDA rules and regulations. Using our novel approach, we have a proven track record of helping our clients achieve successful interactions with FDA. To learn more about how we can help you, contact us today.
September 23, 2015
On June 11, 2010, FDA announced the availability of a guidance entitled “Bioequivalence Recommendations for Specific Products.” This document “explained the process that would be used to make...
February 3, 2017
Last month, FDA’s Center for Drug Evaluation and Research (CDER) released its annual guidance agenda, announcing the new and revised draft guidances that the Center plans to publish during the 2017...
June 23, 2022
Draft Guidance June 2022 FDA is announcing the availability of a draft guidance titled, "Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination." This guidance revises...